Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/7668| Occurrence of relative bradycardia and relative tachycardia in individuals diagnosed with COVID-19 | |
| Aravind Natarajan Hao-wei Su Conor Heneghan | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| https://doi.org/10.1101/2022.02.02.22270342 | |
| https://www.medrxiv.org/content/10.1101/2022.02.02.22270342v1 | |
| Background: The COVID-19 disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) has become one of the worst global pandemics of the century causing tremendous human and economic suffering worldwide. While considered a respiratory disease, COVID-19 is known to cause cardiac complications. Wearable devices are well equipped to measure heart rate continuously and their popularity makes them valuable devices in the field of digital health. In this article, we use Fitbit devices to examine resting heart rate from individuals diagnosed with COVID-19. Methods: The Fitbit COVID-19 survey was conducted from May 2020 - June 2021. We collected resting heart rate data from 7,200 individuals (6,606 symptomatic, 594 asymptomatic) diagnosed with COVID- 19 between March 2020 - December 2020, as well as from 463 individuals diagnosed with influenza between January 2020 - December 2020. Data from healthy individuals served as a control, in order to model the seasonal variation. We also computed heart rate variability and respiratory rate data for symptomatic COVID-19. Findings: Resting Heart Rate is elevated during COVID-19 symptom onset, with average peak increases relative to the baseline of 1.8%+/-0.1% (3.4%+/-0.2%) for females (males), where the quoted numbers are mean and standard error of the mean. After the initial peak, the resting heart rate decreased and reached a minimum on average ~ 13 days after symptom onset. The minimum value relative to the baseline is more negative for females (-1.75% +/- 0.1%) compared to males (0.08% +/- 0.2%). The resting heart rate then increased, reaching a second peak on average ~ 28 days from symptom onset, before falling back to the baseline ~ 112 days from symptom onset. All estimates vary with disease severity. Interpretation: The resting heart rate is modified for several months following a COVID-19 diagnosis. Interestingly, this effect is seen with seasonal influenza also, although the bradycardia minimum and the second tachycardia peak are often more pronounced in the case of symptomatic COVID-19. By computing resting heart rate daily, wearable devices can contribute to monitoring wellness during recovery from COVID-19, and seasonal influenza. Funding: A.N., H.-W.S., and C.H. are supported by Fitbit Research, Google LLC. | |
| medRxiv and bioRxiv | |
| 03-02-2022 | |
| Preimpreso | |
| https://www.medrxiv.org/ | |
| Inglés | |
| Epidemia COVID-19 | |
| Público en general | |
| VIRUS RESPIRATORIOS | |
| Versión publicada | |
| publishedVersion - Versión publicada | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| Occurrence of relative bradycardia and relative tachycardia in individuals.pdf | 6.01 MB | Adobe PDF | Visualizar/Abrir |